Our Gratitude and Reflection for 2021

Hello,
‘Tis the season to sit back and reflect on the year behind us. To be with shorter days and spend time with friends and family.
What are you grateful for this past year?
At ATMA, it has been quite a year to be grateful. Health Canada has approved dozens of Section 56 Exemptions through many different Doctors, companies and non-profits ATMA is honored to be part of this. Thank you, Health Canada!
In December, ATMA supported four palliative applicants with their Psilocybin Therapy experience. What a gift to witness the breakthroughs happening in these sessions to experience the heart-opening and healing occurring with these clients is just magic!
Also, in December, in a ground-breaking fashion, Health Canada approved three exemptions for treatment-resistant anxiety, depression and PTSD, which is outstanding and slowly opening the door to helping more people.
ATMA is committed to helping create a foundation for Psilocybin Therapy to be part of mainstream therapy. Through our Healthcare Professional training program and experiential trials, we hope to support this new therapy becoming accessible.
Currently, ATMA is only accepting Section 56 Exemption applications for people with an end-of-life diagnosis.
Deep gratitude to all the Therapists, Doctors, Nurses, advocates, and other healthcare professionals for helping move the needle forward in this new therapy.
Thank you so much for being part of this great movement
Love and Light
The ATMA Journey Team

More News and Media:

ATMA Submits Phase II Clinical Trial Application, Assessing Psilocybin Efficacy in Healthcare Professionals Suffering From COVID-19-Related Mental Wellness Challenges.

CALGARY, AB, May 10, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of its innovative psychedelic-assisted therapy solutions, announced the submission of its N-500 Phase II Psilocybin Clinical Trial to Health Canada today. This trial is aimed at studying the potential relief of COVID-19-associated mental health concerns in healthcare professionals, as well

Health Canada Provides a No-Objection Letter to Atma Journey Centers: A Clinical Trial Assessing Psilocybin Safety and Exploring Psychological Outcome in Licensed Medical Practitioners

CALGARY, AB, Jan. 7, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”) has been granted a No Objection Letter (“NOL”) by Health Canada, a crucial step towards opening ATMA’s first sponsored clinical trial. The trial participants are licensed health care providers enrolled in a psychedelic-assisted therapy program. The trial’s primary goal will be to document

Working magic?

Mushrooms are having a moment, reports Gayle MacDonald, most notably in the treatment of mental-health disorders and PTSD.

A Bold New Approach to Mental Health

Jonathan Lubecky and Tony White are but a few of the thousands of examples that the impact that Psychedelic-Assisted Therapy can have on those suffering from mental health conditions.

Scroll to Top